NBS-NewBorn Screening

Home » NBS-NewBorn Screening

What is NBS?

Newborn screening is a simple test performed 48 hrs. after birth that enables early detection of serious and life-threatening conditions which may lead to mental/physical retardation or early death, thereby preventing adverse health outcomes and helping the baby lead a normal healthy life. 

The affected baby looks healthy at birth but may be born with a serious medical condition called Inborn errors of Metabolism (IEM) which cannot be diagnosed until specifically tested for. If not tested and treated right after birth, it can lead to irreversible damage. 

Early & accurate diagnosis of these disorders is very important in determining outcome, and hence New born genetic screening is recommended by medical councils across the world and NBS is now compulsory (Paid for by Government) in more than 50 countries across the globe. 

For its contribution to the child health NBS program has been voted as one of the TOP TEN Great Public Health Achievements in USA in the last decade. It has saved lives of millions of babies across the world and helped them live a normal life. 

Benefits of NBS

The biggest benefit of NBS is early detection of the disorders and prevention of untoward outcomes with early intervention. Early detection allows early treatment which usually involves a change in diet or medication that can help the baby live a normal life. 

Highest Testing sensitivity: Disorder detection rate is 95%. (The highest in its class). 

Since these metabolic disorders are not apparent at birth, it’s impossible to suspect and diagnose these disorders until they are specifically tested for through NBS. 

Some of the conditions that can be diagnosed in advance and prevented are: 

Why every baby needs this test?

Newborn Screening (NBS) is a simple yet extremely important test, performed soon after birth to identify harmful and potentially serious but treatable medical conditions in a newborn baby. The affected baby may look healthy at birth as there is no external physical defect, and hence difficult for the patient or even the doctor to identify. If not detected and treated right after birth, these conditions may lead to irreversible physical and mental disabilities and a whole lot of complications affecting the child’s quality of life in years to come.

Such as:

Today, many such serious medical conditions can be identified through New Born Screening (NBS) as early as the 3rd day of life, before they cause irreversible harm to the baby.

Early detection helps parents and doctors, take simple precautionary measures like diet modifications, special infant formula feed, or medication in some cases to prevent serious adverse health outcomes and help the baby live a healthy life.

Newborn screening over the years has saved millions of new born babies and is now mandatory in more than 50 + countries, and is strongly, recommended by pediatric associations across the world including India.

Today, many such serious medical conditions can be identified through New Born Screening (NBS) as early as the 3rd day of life, before they cause irreversible harm to the baby.

Early detection helps parents and doctors, take simple precautionary measures like diet modifications, special infant formula feed, or medication in some cases to prevent serious adverse health outcomes and help the baby live a healthy life.

Newborn screening over the years has saved millions of new born babies and is now mandatory in more than 50 + countries, and is strongly, recommended by pediatric associations across the world including India.

How the NBS Test is performed?

Step 1 : Register

Register for Navigene Baby Screen and select the package you want for your baby in consultation with your doctor or Navigene Experts.

Sampling

Based on the package selected, collect the Urine and/or Blood sample on the special collection kits provided at time of registration and send it to Navigene or call us for a pickup (A Navigene partner hospital will do this for you.

Results

Navigene will send a comprehensive and easily interpretable report within 1-2 days followed by any assistance as required.

How sample is collected/ Sample collection procedure

Navigene’s Newborn Screening test involves a simple and non-invasive process for sample collection. Based on the package chosen, either a urine sample or a few drops of blood, or both, need to be collected on special filter papers provided in the kit.

The Collection Process:

Preparation

Special sample collection kits with filter paper are provided by Navigene.

1
Timing is Key

The sample has to be collected only after 48 hours of birth and only after 24 hours of first feed. Newborn Screening (NBS) can be performed as early as the 3rd day of life. While the test is typically done 24 to 72 hours after birth, there is no age limit for the BabySecure Newborn Screening test; sooner is better, but it can still be done if the initial window is missed.

2
Blood Sample (Heel Prick)

For blood collection, a trained staff will take a few drops of blood from the baby's heel. The test is performed by a simple prick on the baby's heel and collecting a few drops of blood on a special filter paper card. The heel prick does not cause any harm to your baby. A fresh disposable specialized needle called a 'Lancet' is used for every baby, ensuring no chance of your baby getting any infection.

3
Urine Sample

For urine collection, 10-15 ml urine is soaked onto a special filter paper.

4
Sending the Sample

Once collected, send the sample to Navigene or call us for a pickup. A Navigene partner hospital will also do this for you.

5
NBS 4

Our Advanced Technology: At Navigene, these tests are based on state-of-the-art, highly accurate technologies of Gas Chromatography Mass Spectrometry (GC-MS) and Tandem Mass Spectrometry (MS-MS). These are considered cutting-edge technologies in newborn screening internationally.

Conditions screened

Condition Adverse Effects Treatment / Management
Congenital Hypothyroidism (CH): CH is a lack of thyroid hormones present from birth. Infants are usually clinically normal at birth, due to the presence of maternal thyroid hormones. Mental retardation, Hearing loss, Stunted growth, Speech delay, and behavior problems. Damage to the brain and nerves is usually permanent and cannot be reversed. Supplemented with thyroxine which is easy, inexpensive, and very safe.
Galactosemia: Inability to digest Galactose, a simple sugar found in breast milk, many infant formulas, and milk products. This condition can harm the baby’s eyes; can cause serious liver and brain damage and even death. A special milk-free diet as soon as the condition is found can prevent problems.
Biotinidase Deficiency: Lack of an enzyme called biotinidase. Seizures, developmental delays, eczema, and hearing loss. Oral supplementation of BIOTIN (sometimes called vitamin B7).

Our NBS test panels / NBS customizable packages

Test Disorders Covered Sample Required Technology Used
NBS – 3 Congenital Hypothyroidism, Congenital Adrenal Hyperplasia & G6PD deficiency Dried Blood Spot Biochemistry & ELISA
NBS – 4 NBS 3 + Cystic Fibrosis Dried Blood Spot
NBS – 6 NBS 3 + Galactosemia, Biotinidase & Phenylketonuria (PKU) Dried Blood Spot
NBS – 7 NBS 4 + Galactosemia, Biotinidase & Phenylketonuria (PKU) Dried Blood Spot
NBS 50 Covers 50 Disorders (excluding those in NBS 6)
1. Amino Acid profile
2. Acylcarnitine Profile
Dried Blood Spot MS-MS (Tandem Mass Spectrometry)
NBS 110 Most comprehensive package covering 110 disorders:
1. Organic Acidemia
2. Fatty Acid Oxidation Disorders
3. Amino Acid Disorders
4. Sugar Metabolism Defects
5. Purine, Pyrimidine Disorders
6. Peroxisomal Disorders
Urine Sample on special filter paper GC-MS
NBS 31 Covers 31 most common and critical disorders affecting neonates (a subset of NBS 110)
NBS 110 + 3 Tests for disorders in NBS 110 + NBS 3 Urine Sample & Dried Blood Spot (Non-invasive) GC-MS & Biochemical Analysis
NBS 31 + 3 Tests for disorders in NBS 31 + NBS 3 Urine Sample & Dried Blood Spot (Non-invasive) GC-MS & Biochemical Analysis

Our technology

The tests are based on state-of-the-art, highly accurate technologies of Gas Chromatography Mass Spectrometry (GC-MS) and Tandem Mass Spectrometry (MS-MS) considered to be cutting edge technologies in new born screening internationally.

Your report / Post screening support

Navigene will send a comprehensive and easily interpretable report within 1-2 days followed by any assistance as required. Both e-copy and a physical copy are provided.

Important Note: Sample has to be collected only after 48 hours of birth and only after 24 hours of first feed.

In case a baby is tested positive for any of the conditions, Navigene apprises the parents and the doctor about the result and follow up investigations if needed. Navigene can also arrange a consultation with Genetic Metabolic Experts for further treatment/therapy recommendation. Navigene also provides requisite Genetic Counselling to the family.

Trusted Partner for NBS

1. Navigene is one of the pioneers in the NBS space in India with 30+ years of combined experience in the New Born Screening space, has detected several cases of these disorders  thereby saving new borns from future problems. 

2. Navigene is now trusted by all major hospitals, clinics, nursing homes, IVF centers and birthing centers in India, as well as by international clients.

3. Navigene is an NABL accredited (Mc, 25488) laboratory and has also successfully passed several international-quality assurance programs. 

NBS Myth Buster

1 Myth

My baby looks healthy, so they don't need screening.

Fact

Most infants with these conditions show no sign of illness immediately after birth.

2 Myth

Newborn screening can cure genetic disorders.

Fact

Your baby cannot be cured. But early treatment can prevent medical problems and help the baby lead a healthy life.

3 Myth

If my baby tests positive, it means they are definitely sick and there's nothing that can be done.

Fact

A positive screening result means further investigation is needed, not a definite diagnosis. Navigene apprises parents and the doctor about the result and follow-up investigations if needed. While these conditions cannot be "cured," starting treatment very early in life can prevent related medical problems, allowing the baby to lead a healthy and normal life.

4 Myth

Newborn Screening involves painful procedures for my delicate baby.

Fact

The process is simple and non-invasive. For blood collection, a trained staff performs a simple heel prick using a fresh, disposable specialized needle (Lancet), which does not cause any harm to your baby and ensures no chance of infection. Alternatively, some of our comprehensive tests can utilize a simple urine sample.

5 Myth

All Newborn Screening tests are the same, offering similar coverage.

Fact

Navigene offers the most comprehensive portfolio of Newborn Screening tests in the world. Our customized packages range from screening for 4 basic disorders up to 110 or even 114 such disorders, providing extensive protection tailored to your needs

Client Testimonials

Frequently Asked Questions

My baby looks healthy. Is this still needed?

Yes, it is still needed. Most infants with these conditions show no sign of illness immediately after birth.

Navigene will inform parents and the doctor, recommend follow-up investigations, and can arrange consultations with Genetic Metabolic Experts for treatment/therapy and genetic counseling.

The test is a simple and non-invasive process. The heel prick does not cause any harm to your baby, and a fresh, disposable lancet is used to prevent infection. 

Navigene sends a comprehensive report within 1-2 days. If positive, parents and doctors are apprised of results, and follow-up investigations, expert consultations, and genetic counseling can be arranged. 

No, these disorders cannot be cured. However, early treatment can prevent related medical problems, allowing the baby to lead a healthy life. 

Yes, Newborn Screening identifies serious and often life-threatening conditions that, if undetected, can lead to severe mental and physical disabilities, organ damage, or early death.

The test looks for over 100 disorders

You should consult your doctor or Navigene Experts to select the appropriate screening package. Also, ensure the sample is collected only after 48 hours of birth and 24 hours of the baby’s first feed. 

DBS refers to Dried Blood Spot, which is the method where a few drops of blood are collected from the baby’s heel onto a special filter paper or Guthrie card for testing. 

A trained staff will collect the sample. This can often be done by a Navigene partner hospital. 

The tests use highly accurate, state-of-the-art technologies like GC-MS and MS-MS. Navigene is NABL accredited and consistently clears international quality assurance programs. However, as with all screening tests, there is a chance of false positives and false negatives. 

You will get the test results within 1-2 days, with a turnaround time of 24-48 hours.

Yes, even if you miss the early 72-hour window, you can still do the test as there is no age limit. However, sooner is better so treatment can start immediately if a disorder is identified.

Newborn screening is strongly recommended by pediatric associations across the world, including India. The documents state it is mandatory in over 50 countries, but do not explicitly confirm it is mandatory across all of India. 

Dr. Dipanjana Datta

Consultant Geneticist & Senior Genetic Counsellor

Dr. Dipanjana Datta is a molecular geneticist with a PhD in Human Genetics from the Indian Institute of Chemical Biology, followed by a postdoctoral fellowship at Virginia Commonwealth University—specializing in neuromuscular disorders—and holds certification as a medical geneticist.

She leads in prenatal and reproductive genetics, rare disease diagnostics , nephrogenetics, and neuromuscular disorders. As a senior research scientist, she participated in the Indian Genome Variation Consortium, contributing to its major genomics efforts.Her scholarly work includes peer-reviewed publications in journals such as PNAS, Journal of Neurology, and PLOS One. She pioneered India’s first public-health-based rare disease screening clinics in collaboration with the Kolkata Municipal Corporation and holds a patent for a biomarker-based diagnostic approach in head and neck cancer.

Lakshita Chauhan

Head - Genomics, Geneticist & Genetic Counsellor

Lakshita Chauhan is one of India’s foremost and most respected genetic counselors, widely recognized for her contributions to the field of medical genetics. She is the first genetic counselor to have served the Indian Armed Forces, where she established the inaugural genetics clinic and laboratory with clinical Geneticist, New Delhi. Her journey began at the National Inherited Disorders Administration (NIDAN) Kendra under the Department of Biotechnology, where she laid the foundation as its first Genetic Counselor.

With a distinguished career spanning preconception, prenatal, postnatal, pediatric, neurogenetic, and oncogenetic counseling, Lakshita combines deep expertise in genomic data analysis with a compassionate, non-directive counseling approach. She is dedicated to helping patients and families navigate complex genetic findings, understand their implications, and find strength in the face of uncertainty.

In recognition of her groundbreaking work and leadership in the field, Lakshita was awarded the National Youth Icon Award in Genetic at 3rd National Symposium on genetic diseases held at New Delhi.

Currently, as part of Navigene, she is spearheading the development of the genetics division—building it from the ground up to position the institution as India’s premier center for genetic diagnostics and research. Alongside her clinical and research endeavors, she is a passionate advocate for rare genetic disorders, frequently engaging as a keynote speaker to raise awareness and foster understanding of children’s genetic conditions.

Lakshita Chauhan stands at the intersection of science, compassion, and advocacy—committed to shaping the future of genetics in India and empowering individuals and families through knowledge and care.

Mr. Anirvan Dam

Director, Sales-Retail

Anirvan Dam serves as the Director of Sales – Retail at Navigene Genetic Science Pvt. Ltd., where he spearheads both retail and institutional sales initiatives. Holding a Post Graduate Diploma in Business Management (PGDBM) with a specialization in Marketing, Anirvan is also an alumnus of the National Institute of Sales.

With a robust career spanning corporate and retail sales across diverse sectors, Anirvan has consistently demonstrated a deep understanding of market dynamics and customer engagement strategies. His entrepreneurial acumen is exemplified by the founding of The Kids Clinic (TKC), a pediatric healthcare venture under Kids Medical Systems Pvt. Ltd., which expanded from a single clinic in Dombivli to over 15 locations through strategic partnerships and franchise models.

At Navigene, Anirvan adopts a holistic approach to sales, integrating cross-functional collaboration to enhance the overall sales experience. His leadership is marked by the implementation of innovative strategies that drive consistent growth and elevate customer satisfaction. Anirvan is a passionate cricket enthusiast and regards traveling as a natural expression of his zest for life.

Mr. Vinod R Jadhav

Director

Vinod Ramchandra Jadhav represents the first generation of SAVA’s founding family and served as the Managing Director of the company from 2004 to 2013. After completing Diploma in Mechanical Engineering in 1990 from Cusrow Wadia Institute of Technology Pune India, Vinod worked for 13 years for world class organizations like Larsen & Toubro, Mercedes- Benz, Fiat Automobiles & Tata AutoComp Systems in various roles across Sales, Marketing, distribution, Product Management, Import-Export logistics, International Taxation & Transfer Pricing.

In 2003, Vinod founded Anagha Pharma as a global pharmaceutical trading company. The company transformed into SAVA Healthcare in 2010 after acquiring two manufacturing units in Gujarat and Karnataka and establishing an R&D center in Pune. SAVA Healthcare has been involved in International Business, SAVAVET, SAVA Herbals and CRAMS activities then on.

Vinod is Honorary member of Rotary Club of Pune Heritage, a recipient of Major Donor Crystal and “Paul Harris Fellow” Pin from Rotary International. He was recently conferred the prestigious “Diamond of the CWITAN” award from his alma mater.

Vinod is also an investor & director in various enterprises around the world and supports philanthropic initiatives in education of underprivileged children, girl child & healthcare for the needy.

At Navigene, Vinod not only served as the first investor—continuing to fund its growth—but has also supported the company’s journey over the past 13 years with vital guidance, invaluable networks, and unwavering support

Mr. Surojit Nandy

Co-Founder | Director & COO

Surojit Nandy is a seasoned entrepreneur with over two decades of experience in founding and scaling startups across diverse sectors, including healthcare, finance, real estate, and human resources.

He co-founded Navigene alongside Dr. Rishi Dixit, investing through his venture capital firm Incucapital Advisors and served as an investor and strategic advisor. Over the years, Surojit became deeply involved in various facets of Navigene’s operations, culminating in his appointment as full-time Chief Operating Officer and Director in 2024. In his current role, he oversees the company’s overall operations and spearheads key strategic initiatives.

Surojit is a Chemistry (Hons.) graduate from the University of Calcutta and holds an MBA from Symbiosis Institute, Pune. He began his career in IT consulting at Satyam Computers, working with European clients, before embarking on his entrepreneurial journey. Outside of work, Surojit is an avid reader, passionate runner, and has recently developed an interest in scriptwriting

Dr. Rishi Dixit

Co-Founder | Managing Director & CEO

Dr. Rishi Dixit is a thought leader in healthcare with over 14 years of expertise in preventive screening and diagnostics, having a strong focus on the early detection of genetic disorders. As Co-Founder, Managing Director, and CEO of Navigene Genetic Science Pvt. Ltd., he has been at the forefront of developing and implementing innovative, next-generation diagnostic solutions that bridge the gap between advanced science and real-world healthcare needs.

He has partnered with state governments across India to drive large-scale screening initiatives for hemoglobinopathies (sickle cell disease and thalassemia), especially in rural and tribal regions where the impact is most profound. His efforts combine cutting-edge technology with community engagement through Information, Education, and Communication (IEC) programs, ensuring both accessibility and awareness among vulnerable populations.

An MBBS graduate with an MBA from Sydenham College, Mumbai, Dr. Dixit blends medical expertise with business leadership to shape Navigene’s mission of advancing preventive diagnostics. Beyond his executive responsibilities, he remains actively involved in core research and development, continuously pushing the boundaries of innovation in genetic science.

Outside of work, Dr. Dixit is a passionate cricket enthusiast and nurtures a personal aspiration to learn a musical instrument.